Front-Line Therapy in Papillary Renal Cancer: Live Session From The Uromigos Live & Unplugged 2024

By Brian Rini, MD, FASCO, Thomas Powles, MBBS, MRCP, MD, Laurence Albiges, MD, PhD, David F. McDermott, MD, Hans Hammers, MD, PhD - Last Updated: October 2, 2024

Moderator Brian Rini, MD, and panelists Thomas Powles, MD, MBBS; Laurence Albiges, MD; David McDermott, MD; and Hans Hammers, MD debate front-line therapies in papillary renal cancer at the Uromigos Live & Unplugged 2024 in Nashville, Tennessee.

Click the image below to access the slide PDFs.

Post Tags:Uromigos Live 2024: Focus on Kidney Cancer

The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025

Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.

Impact of Insurance Status on Survival Outcomes in Metastatic RCC

Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025

Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.

PSMA-Guided MDT Shows Promise in Oligometastatic RCC

Emily MenendezRenal Cell Carcinoma Diagnostics | March 4, 2025

A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.

Expanding Treatment Horizons: Novel Approaches in RCC and Non-Clear Cell Disease

Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025

The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.

Multidisciplinary Approaches to Managing IRAEs in RCC

Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025

The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.

Front-Line Therapy in Papillary Renal Cancer: Live Session From The Uromigos Live & Unplugged 2024

Related Posts